Beta cell dysfunction as an acute and a post acute sequelae of COVID19

β 细胞功能障碍是 COVID19 的急性和急性后遗症

基本信息

批准号：
10505064
负责人：
Senta K Georgia
金额：
$ 58.48万
依托单位：
CHILDREN'S HOSPITAL OF LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-01 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10505064
关键词：
2019-nCoV Accident and Emergency department Acute Address Adult Affect Animal Model Animals Atrophic Autopsy Beta Cell Biological Assay Biological Models COVID-19 COVID-19 impact COVID-19 pandemic COVID-19 pathogenesis COVID-19 patient COVID-19 survivors Cadaver Cell Respiration Cell Survival Cell physiology Cellular Metabolic Process Cessation of life Clinical Cohort Studies DNA DNA Methylation Data Development Diabetes Mellitus Diabetic Ketoacidosis Disease Face Functional disorder Future Glucose Goals Health Human Hyperglycemia In Vitro Infection Injury Insulin Insulin-Dependent Diabetes Mellitus Islets of Langerhans Transplantation Kidney Literature Long COVID Long-Term Effects Macaca mulatta Measures Mediating Metabolic Metabolism Mitochondria Modeling Molecular Morphology Mus Non-Insulin-Dependent Diabetes Mellitus Odds Ratio Outcome Pancreas Paper Pathogenesis Pathology Patients Physiological Plasma Post-Acute Sequelae of SARS-CoV-2 Infection Prevalence Primates Recovery Registries Reporting Reproducibility Resolution Respiratory System SARS-CoV-2 infection Sampling Secondary to Serum Stress Structure of beta Cell of islet Study models Symptoms Techniques Testing Therapeutic Intervention Transplantation Viral Pathogenesis acute infection blood glucose regulation capsule cell free DNA cell injury clinical phenotype clinically relevant design diabetes pathogenesis experimental study improved in vivo in vivo Model innovation insight insulin dependent diabetes mellitus onset insulin secretion islet methylation pattern nonhuman primate post-transplant prevent severe COVID-19 small molecule

项目摘要

PROJECT SUMMARY Beta cell dysfunction and death are significant pathologies underlying the development of Type 2 diabetes. Our long-term goal is to identify molecular mechanisms restrict beta cell function and survival. During the SARS- CoV2-driven COVID19 pandemic, there are reports of adult COVID19+ patients presenting with diabetic ketoacidosis in emergency rooms. 25% of new-onset type 1 diabetes (T1D) patients presenting with diabetic ketoacidosis in the T1D Exchange registry are COVID19+. Our group has reported a significant increase in the number of new-onset type 2 diabetes patients presenting in diabetic ketoacidosis. This suggests that the pathogenesis of COVID19 may have acute and specific effects on pancreatic beta cell function. One of the barriers to understanding how SARS-CoV2 infection may affect beta cell function and survival in patients is the limited number of physiologically relevant animal models to study. We have capitalized on unique access the pancreas of SCV2-innoculated animals to model and understand how the infection may affect beta cell function and survival. Our preliminary data that shows: (1) SARS-CoV2 directly infects beta cells, (2) SARS-CoV2 infection causes dramatic morphological changes in islet, (3) SARS-CoV2 infection shifts beta cell metabolism to glycolytic profile, and (4) SARS-CoV2 infection results in decreased in beta cell function and survival. The objective of this proposal is to define the mechanisms that drive the post-acute consequences of COVID19-mediated beta cell injury in vivo. There is controversy in the literature regarding if SARS-CoV2 directly infects beta cells and affects beta cell function and survival or if the disruption of glucose homeostasis in patients is secondary. We hypothesize that SARS-CoV2 infection reprograms cellular metabolism and induces necroptosis, thus leaving hosts susceptible to beta cell dysfunction acutely and as a post-acute sequelae of COVID19. These highly innovative experiments capitalize on a unique and clinically relevant model system and employs cutting edge techniques to assess how beta cell survival and metabolism are affected by SARS-CoV2 infection. These experiments will provide critical mechanistic insight to the underpinnings of the emerging clinical phenotype of acute hyperglycemia, diabetic ketoacidosis, and potentially lifelong diabetes that may afflict a significant number of patients who have recovered from COVID19.

项目概要 β 细胞功能障碍和死亡是 2 型糖尿病发展的重要病理基础。我们的长期目标是确定限制β细胞功能和存活的分子机制。非典期间—— 冠状病毒驱动的新冠肺炎大流行，有报告称成年新冠肺炎+患者出现糖尿病急诊室的酮症酸中毒。 25% 的新发 1 型糖尿病 (T1D) 患者出现糖尿病症状 T1D Exchange 注册表中的酮症酸中毒为 COVID19+。我们小组的报告显示，出现糖尿病酮症酸中毒的新发 2 型糖尿病患者数量。这表明 COVID19 的发病机制可能对胰腺 β 细胞功能产生急性和特异性影响。中的一个了解 SARS-CoV2 感染如何影响患者 β 细胞功能和生存的障碍是可供研究的生理相关动物模型数量有限。我们利用了独特的访问权限对 SCV2 接种动物的胰腺进行建模并了解感染如何影响 β 细胞功能和生存。我们的初步数据显示：(1) SARS-CoV2 直接感染 β 细胞，(2) SARS-CoV2 感染导致胰岛形态发生巨大变化，(3) SARS-CoV2 感染改变 β 细胞代谢 (4) SARS-CoV2 感染导致 β 细胞功能和存活率下降。该提案的目的是定义驱动急性后后果的机制 COVID19介导的体内β细胞损伤。文献中关于 SARS-CoV2 是否存在争议直接感染 β 细胞并影响 β 细胞功能和存活，或者如果葡萄糖稳态被破坏病人是次要的。我们假设 SARS-CoV2 感染会重新编程细胞代谢并诱导坏死性凋亡，从而使宿主容易受到急性β细胞功能障碍的影响，并且作为急性后 COVID19 的后遗症。这些高度创新的实验利用了独特的临床相关模型系统并采用尖端技术来评估 β 细胞存活和代谢如何受到影响 SARS-CoV2 感染。这些实验将为理解这一现象的基础提供关键的机制见解。急性高血糖、糖尿病酮症酸中毒和潜在的终身糖尿病的新出现的临床表型可能会影响大量从新冠病毒中康复的患者。